Monitoring recommendations
Monitor:
- FBC every two weeks for the first six months; then every two months
- LFTs and blood pressure - measured monthl for the first six months and then every two months
Stop drug, inform specialist if:
- WBC < 3.5 x 10^9/l, or,
- platelets < 150 x 10^9/l, or,
- if ALT > twice upper limit of normal on two occasions
Note in cases of severe haematological reactions, leflunomide and concomitant myelosuppressives must be discontinued; also a leflunomide wash-out procedure must be initiated.
Reference:
- Doctor magazine (December 2002). Disease-modifying anti-rheumatic drugs.
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.